前列腺癌基因组学研究对于理解前列腺癌生物学非常重要，它可以为临床提供相关的亚型分层、在精准医学背景下开发新的预后和预测标志物以及开发新的靶向治疗方案。近期研究提供了前列腺癌的基因组、表观遗传组和蛋白质组的详细见解，包括原发性和转移性去势抵抗型前列腺癌(mCRPC)。许多突变已被发现，包括早期的癌变和进展，以及在治疗影响下晚期导致耐药的突变。发现了大量特征性的突变信号通路，如发现DNA修复通路的突变在23％的mCRPC中，这表明可能对PARP抑制剂有响应。前列腺癌的多灶和肿瘤内基因组异质性使得基因组的临床应用变得复杂。尽管在理解前列腺癌基因组方面已经有了很大的进展，并且与其日常应用相关的临床研究正在进行，但前列腺癌基因组学仍需要在前列腺癌患者中找到其标准广泛的日常应用。

The studying of prostate cancer genomics is important for understanding prostate cancer biology, it can provide clinically relevant stratification into subtypes, the development of new prognostic and predictive markers in the context of precision medicine, and the development of new targeted therapies. Recent studies have provided detailed insight into genomics, epigenomics and proteomics of prostate cancer, both primary and metastatic castration-resistant (mCRPC). Many mutations have been discovered, both those that occur early in the carcinogenesis and progression as well as those responsible for the resistance to therapy occurring later under the influence of treatment. A large number of characteristic mutated signaling pathways has been identified, e.g. the mutations in DNA repair pathway were found in 23% of mCRPC, which suggests potential response to PARP inhibitors. Multifocality and intralesional genomic heterogeneity of prostate cancer make the clinical application of genomics complicated. Although a great progress was made in understanding prostate cancer genomic, and clinical studies related to its routine application are ongoing, prostate cancer genomics still needs to find its standard wide routine application in patients with prostate cancer.